BLCO ▼ -2.7% - Bausch + Lomb Corporation
$BLCO Bausch + Lomb's Phase 2 BL1332 Trial Misses Primary Endpoint Despite Positive Pain Relief Signals ? • Primary Endpoint: Failed to achieve statistically significant pain reduction over 24 hours following eye surgery. • Efficacy: Both doses showed numerically greater pain relief. At 6 hours, complete pain relief reached 14.0%–14.6% versus 3.7% with placebo. • Safety: Well tolerated, with no treatment-related or serious adverse events. • Next Steps: Company plans FDA discussions regarding further development and potential Phase 3 trial design.
19-NOV-2026 04:19 PM ET
Share this post
More filings for $BLCO
BLCO ▼ -2.7% - Bausch + Lomb CorporationNov 19, 2026BLCO ▼ -0.3% - Bausch + Lomb CorporationOct 12, 2026
View full $BLCO filing history →💬 Comments
Loading comments…
Leave a comment
